Oncology News | pharmaphorum

News

AZ, Daiichi Sankyo file Dato-DXd for second indication

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (

News

Ipsen licenses Sutro ADC in $900m deal

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category.

News

Japan clears first CLDN18.2 drug, Astellas’ Vyloy

Astellas has become the first drugmaker to bring a claudin 18.2 (CLDN18.2) targeted therapy to regulatory approval, getting a green light in Japan for Vyloy as a treatment

News

Nuvation Bio nears commercial stage with AnHeart buy

Nuvation Bio has accelerated its development into a commercial-stage biotech with a deal to acquire AnHeart Therapeutics and its late-stage lung cancer therapy taletrectin

News

FDA turns down Regeneron bispecific blood cancer antibody

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL).

News

Clasp Therapeutics chief executive Rob Ross

Clasp emerges with $150m for safer T-cell engagers

Clasp Therapeutics has burst onto the T-cell engager (TCE) scene with $150 million in funding for a platform that aims to improve the safety of the class, which is current

AZ, Daiichi Sankyo file Dato-DXd for second indication

Ipsen licenses Sutro ADC in $900m deal

Japan clears first CLDN18.2 drug, Astellas’ Vyloy

Nuvation Bio nears commercial stage with AnHeart buy

FDA turns down Regeneron bispecific blood cancer antibody

Clasp emerges with $150m for safer T-cell engagers

Novo Nordisk gets FDA okay for Wegovy pill

How to meet your physicians where they are online

News

Editor's Picks